Timing and why we’re all VCs
TechCrunch LA
FEBRUARY 20, 2019
From the article: Mithril had its best moment yet last week when a portfolio company, Auris Health, sold to Johnson & Johnson for more than $3 billion — returning at least $500 million to the fund. Mithril is struggling to compete against ferocious competition in the growth-stage equity market. Peter Kim via Getty Images.
202 
Let's personalize your content